

Member FINRA/SIPC

Toll-Free: 561-391-5555 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

Anavex Life Sciences Corp. (NASDAQ/AVXL)

June 28, 2021

BUY: Biomarkers Continue to Correlate – This Time, It's Parkinson's Disease Dementia Patients

Jason Kolbert

 Senior Healthcare Analyst
 jkolbert@dawsonjames.com

This is now the second independent placebo-controlled clinical study of ANAVEX2-73 (a Phase 2 study) that confirms the predictive biomarker of response established with SIGMAR1 mRNA expression. Now, both the ANAVEX2-73-PDD-001 Parkinson's disease dementia study and the recently reported ANAVEX2-73-RS-001 U.S. Rett syndrome study are consistent with the proposed mechanism for ANAVEX®2-73.

Investment Highlights

What's the data? (Adapted from the press release):


- ANAVEX2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA ($p = 0.029$) and MDS-UPDRS Part III ($p = 0.024$) and MDS-UPDRS Total ($p = 0.038$) 14.51-point MDS-UPDRS (Movement Disorder Society - Unified Parkinson Disease Rating Scale) Total score improvement compared to placebo ($p = 0.034$). Data strengthens regulatory pathway for Parkinson's disease as new therapeutic target population for ANAVEX2-73.
- ANAVEX2-73 high dose demonstrated statistically significant improvements compared to placebo (ITT population) for MDS-UPDRS Total score ($p = 0.034$). From baseline to end of trial at 14 weeks, MDS-UPDRS Total score improved by -10.98 points in the ANAVEX®2-73 high dose group and worsened by 3.53 points in the placebo group, an adjusted mean difference of -14.51 points ($p = 0.034$). This corresponds to a relative improvement of 18.9 % over 14 weeks.
- Treatment with ANAVEX2-73 not only slows the progression of motor and non-motor symptoms in moderately advanced patients with Parkinson's. ANAVEX2-73 also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson's disease symptom severity, MDS-UPDRS Total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX2-73's global capability of slowing and reversing symptoms that progress in Parkinson's disease.

Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2030. Our model assumes multiple financial raises, and as such, our share count is based on a projected, fully diluted out-year basis. Given the early nature of the company and its dependence on clinical trial outcomes in the CNS space, we apply a probability of success (50%) in our models. On top of this, we also add a 30% risk rate in our free cash flow to the Firm (FCFF), our discounted EPS (dEPS), and sum-of-the-parts (SOP) models. We equal weight and average these metrics and then round to the nearest whole number to derive our price target.

Risks to our thesis include: (1) commercial; (2) regulatory; (3) clinical; (4) market share; (5) financial; (6) investment; and (7) intellectual property.

Current Price	\$30.08
Price Target	\$35.00

Precision Medicine



Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis

Stock Data			
52-Week Range	\$3.65	-	\$30.20
Shares Outstanding (mil.)	72.4		
Market Capitalization (mil.)	\$2,178		
Enterprise Value (mil.)	\$2,159		
Debt to Capital	0%		
Book Value/Share	\$0.56		
Price/Book	10.4		
Average Three Months Trading Volume (K)	1,531		
Insider Ownership	3.6%		
Institutional Ownership	26.5%		
Short interest (mil.)	9.7%		
Dividend / Yield	\$0.00/0.0%		




Exhibit 1. Income Statement (\$ in thousands)

Anavex Life Sciences Corp																	
Anavex: YE Sept 30	2019A	2020A	1Q21A	2Q21A	3Q21E	4Q21E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	
Revenue																	
Anavex2-73 AD U.S.		-	-	-	-	-	-	-		191,826	338,892	498,171	666,126	533,641	622,073	674,171	
Anavex2-73 AD ROW			-	-	-	-	-	-		555,169	735,599	617,903	642,619	551,582	675,136	803,412	
Anavex2-73 Rett's Syndrome			-	-	-	-	-	67,744	207,296	317,162	395,395	439,967	448,767	457,742	466,897	476,235	
Anavex2-73 Parkinson's Dementia PDD			-	-	-	-	-	-	-	14,229	58,055	88,824	120,801	184,826	219,943	240,366	
Total Product Revenues	-	-	-	-	-	-	-	67,744	207,296	1,078,386	1,527,942	1,644,866	1,878,313	1,727,790	1,984,048	2,194,184	
% Chg																	
% Sequential Growth																	
Milestones																	
% Sequential Growth																	
Total Revenues (\$000)	-	-	-	-	-	-	-	67,744	207,296	1,078,386	1,527,942	1,644,866	1,878,313	1,727,790	1,984,048	2,194,184	
Expenses																	
Cost of Goods Sold (10%)		-	-	-	-	-	-	-	-	74,699	107,449	111,607	130,875	108,522	129,721	147,758	
Accounting and Audit Fees																	
Amortization and depreciation	2	2	0	0	0	0	2	2	2	2	2	2	2	2	2	2	
Bank charges and interest																	
Consulting Fees																	
Insurance																	
Investor relations																	
Legal fees																	
Management fees																	
Office and miscellaneous expense																	
Registration and filing fees																	
Rent and administration																	
Research and Development	22,260	25,232	7,926	6,721	6,754	6,788	28,189	21,886	17,773	14,432	11,720	9,517	7,729	6,276	5,097	4,139	
Salaries and wages																	
Travel																	
Website design and maintenance																	
General and Administrative	6,847	5,857	1,470	2,234	1,611	1,611	6,442	80,000	100,000	75,000	65,000	65,650	66,307	66,970	67,639	68,316	
Operating expenses	31,287	31,088	9,396	8,955	8,365	8,399	35,115	101,887	117,774	164,133	184,171	186,776	204,911	181,769	202,458	220,214	
Oper. Inc. (Loss)	(31,287)	(31,088)	(9,396)	(8,955)	(8,365)	(8,399)	(35,115)	(34,144)	89,521	914,253	1,343,771	1,458,090	1,673,402	1,546,021	1,781,590	1,973,970	
Oper Margin	NM	NM	NM	NM	NM	NM	NM	NM	0	1	1	1	1	1	1	1	
Other income (expense)	2,466																
Research and Development incentive	299																
Interest and financing fees	207							(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)	
Accretion of debt discount	116																
Change in fair value of derivative liability	(151)																
Debt conversion expense	(42)																
Loss on settlement of accounts payable																	
Loss on extinguishment of debt																	
Foreign exchange gain (loss)																	
Financing related charges and adjustments																	
Other non-operating income																	
Non-operating Income (expense)	2,894	-	-	-	-	-	-	(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)	
Financial Income, Net		4,830	1,600	826			2,427										
Financial Expenses, Net	(28,393)	(26,258)	(7,795)	(8,129)	(8,365)	(8,399)	(35,115)	(34,169)	89,496	914,228	1,343,746	1,458,065	1,673,377	1,545,996	1,781,565	1,973,945	
Pretax Income	(28,393)	(26,258)	(7,795)	(8,129)	(8,365)	(8,399)	(35,115)	(34,169)	89,496	914,228	1,343,746	1,458,065	1,673,377	1,545,996	1,781,565	1,973,945	
Pretax Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	
Income Tax Benefit (Provision)	(82)	(23)	(59)	(27)	-	-	(86)	(1,708)	8,950	164,561	389,686	481,161	602,416	602,938	694,810	769,838	
Tax Rate	0	0	0	0	0	0	5%	5%	10%	18%	29%	30%	31%	31%	31%	31%	
GAAP Net Income (loss)	(28,475)	(26,280)	(7,855)	(8,156)	(8,365)	(8,399)	(32,775)	(32,460)	80,547	749,667	954,060	976,903	1,070,961	943,057	1,086,755	1,204,106	
Net Margin	NM	NM	NM	NM	NM	NM	NM	NM	0.39	0.70	0.62	0.59	0.57	0.55	0.55	0.55	
GAAP EPS	(0.65)	(0.45)	(0.12)	(0.12)	(0.12)	(0.12)	(0.48)	(0.45)	1.08	9.65	14.80	11.61	12.23	10.35	11.46	12.20	
Non GAAP EPS (dil)	(0.65)	(0.45)	(0.12)	(0.12)	(0.12)	(0.12)	(0.48)	(0.45)	1.08	9.65	11.80	11.61	12.23	10.35	11.46	12.20	
Wgtd Avg Shrs (Bas)	48,906	58,195	64,295	68,595	68,663	68,732	67,571	68,904	69,180	69,457	69,736	70,015	70,295	70,577	70,860	71,144	
Wgtd Avg Shrs (Dil)	48,906	58,195	64,295	68,595	69,281	69,974	68,036	71,741	74,653	77,685	80,839	84,121	87,537	91,091	94,790	98,639	

Source: Dawson James estimates, company reports

Risk Analysis

Clinical Trial Risk. Anavex is dependent on the outcome of multiple clinical trials. The failure rates associated with disease conditions such as Alzheimer's are historically very high.

Commercial Risk. Anavex hopes to compete in the CNS markets, which have traditionally been dominated by large pharma and biotechnology companies with deep pockets (funding and resources), which may make it difficult for Anavex to compete unless the molecule is deemed to be truly differentiated.

Financial Risk. Anavex is likely to require additional capital raises before the company can be self-sustaining. There can be no guarantees that the company will be able to raise the needed capital.

Investment Risk. Anavex is a small capital company, which can translate into high volatility and risk for investors. The company has no revenues and is dependent on the clinical progress of its therapeutics.

Intellectual Property. Anavex may face I.P. challenges, forcing the company to defend its patents or itself against claims that the company is infringing on other patents. We do know that the lead product is protected by a composition of matter patent to 2033.

Market Share Risk. The central nervous system (CNS) market is competitive and tends to be dominated by large pharma and large well established biotechnology companies.


Regulatory Risk. Anavex, even with good clinical data, could face extensive delays and other regulatory setbacks.

Companies mentioned in this report:

Cassava Science (SAVA Not Rated)

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

Initiated – Buy – July 24, 2019 – Price Target \$16.00
 Update – Buy – July 31, 2019 – Price Target \$16.00
 Update – Buy – August 7, 2019 – Price Target \$16.00
 Update – Buy – September 5, 2019 – Price Target \$16.00
 Update – Buy – September 17, 2019 – Price Target \$16.00
 Update – Buy – October 24, 2019 – Price Target \$16.00
 Update – Buy – December 2, 2019 – Price Target \$16.00
 Update – Buy – December 4, 2019 – Price Target \$16.00
 Update – Buy – February 4, 2020 – Price Target \$16.00
 Update – Buy – February 7, 2020 – Price Target \$16.00
 Update – Buy – May 8, 2020 – Price Target \$16.00
 Update – Buy – May 22, 2020 – Price Target \$16.00
 Update – Buy – June 16, 2020 – Price Target \$16.00
 Update – Buy – July 1, 2020 – Price Target \$16.00
 Update – Buy – October 15, 2020 – Price Target \$16.00
 Update – Buy – November 6, 2020 – Price Target \$16.00
 Update – Buy – December 15, 2020 – Price Target \$16.00
 Price Target Change – Buy – February 19, 2021 – Price Target \$16.0 to \$19.00
 Update – Buy – April 5, 2021 – Price Target \$19.00
 Update – Buy – April 12, 2021 – Price Target \$19.00
 Update – Buy – May 19, 2021 – Price Target \$19.00
 Update – Buy – June 8, 2021 – Price Target \$19.00
 Price Target Change – Buy – June 21, 2021 – Price Target \$35.00
 Update – Buy – June 28, 2021 – Price Target \$35.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with AVXL in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of May 31, 2021, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

As of: 28-Jun-21

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	24	71%	4	17%
Market Perform (Neutral)	10	29%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	34	100%	4	12%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.